NextCure reports positive SIM0505 trial data for gynecologic cancers

June 1, 2026 8:01 AM

NextCure Inc. (NASDAQ: NXTC) and Simcere Zaiming Pharmaceutical Co. Ltd. announced positive Phase 1 dose escalation data for SIM0505, an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found